NCT02736162

Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Routine Clinical Care in Patients With Epilepsy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 61 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.

Detailed description

This study is a retrospective study of participants who received perampanel as primary or secondary monotherapy at approximately 40 centers in Europe, Asia, and Australia. Primary monotherapy is defined as the administration of perampanel in the absence of any concomitant antiepileptic drugs (AEDs). Secondary (conversion) monotherapy is defined as the conversion of perampanel from adjunctive therapy to monotherapy by withdrawing concomitant AEDs.

Conditions

• Epilepsy
• Partial-Onset Seizures
• Primary Generalized Tonic-Clonic Seizures

Interventions

Type	Name	Description
OTHER	No treatment (intervention) was administered

Timeline

• Start date: 2016-04-01
• Primary completion: 2016-06-01
• Completion: 2016-07-01
• First posted: 2016-04-13
• Last updated: 2017-03-09